The value of AI for assessing longitudinal brain metastases treatment response.

Saved in:
Bibliographic Details
Title: The value of AI for assessing longitudinal brain metastases treatment response.
Authors: Andrearczyk V; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Institute of Informatics, HES-SO Valais-Wallis University of Applied Sciences and Arts Western Switzerland, Sierre, Switzerland., Schiappacasse L; Lundin Family Brain Tumor Research Centre, Departments of Oncology & Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Department of Radiation Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Raccaud M; Department of Medical Radiology, Service of Diagnostic and Interventional Radiology, Neuroradiology Unit, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Bourhis J; Lundin Family Brain Tumor Research Centre, Departments of Oncology & Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Department of Radiation Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Prior JO; Lundin Family Brain Tumor Research Centre, Departments of Oncology & Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Cuendet MA; Lundin Family Brain Tumor Research Centre, Departments of Oncology & Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Hottinger AF; Lundin Family Brain Tumor Research Centre, Departments of Oncology & Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Dunet V; Lundin Family Brain Tumor Research Centre, Departments of Oncology & Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Department of Medical Radiology, Service of Diagnostic and Interventional Radiology, Neuroradiology Unit, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Depeursinge A; Lundin Family Brain Tumor Research Centre, Departments of Oncology & Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Institute of Informatics, HES-SO Valais-Wallis University of Applied Sciences and Arts Western Switzerland, Sierre, Switzerland.
Source: Neuro-oncology advances [Neurooncol Adv] 2025 Jan 10; Vol. 7 (1), pp. vdae216. Date of Electronic Publication: 2025 Jan 10 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2632-2498
DOI:10.1093/noajnl/vdae216